Mycophenolate Mofetil (MMF) is primarily used for the prevention of allogeneic organ rejection, particularly in kidney transplantation, and is also applicable to heart and liver transplantation, especially for refractory rejection episodes post-transplantation. It can be co-administered with cyclosporine and corticosteroids. Additionally, MMF is used in the treatment of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, primary glomerulonephritis, and psoriasis. It has also shown efficacy in immune-mediated nephropathies (including Henoch-Schönlein purpura nephritis, refractory nephrotic syndrome, lupus nephritis, and IgA nephropathy), autoimmune liver diseases (particularly in patients unresponsive to conventional therapy), autoimmune pancreatitis (especially IgG4-related disease), refractory idiopathic thrombocytopenic purpura (R-ITP), and myasthenia gravis.